The Kleinstiver Laboratory (www.kleinstiverlab.org) in the Center for Genomic Medicine at Massachusetts General Hospital (MGH) is seeking motivated and enthusiastic candidates to join our team. Our research group engineers and optimizes genome editing technologies to apply them for biomedical research and to treat human diseases. We pursue protein and nucleic protein engineering methods to impart desirable properties into CRISPR-Cas enzymes (e.g. Cas9, Cas12, etc.), for next-generation technologies capable of installing single letter DNA edits (e.g. base editors), for polymerization-based DNA writing approaches (e.g. prime editors, click editors, etc.), for various editors capable of larger sequence edits (e.g. CRISPR-associated transposases (CASTs), transposons, recombinases, etc.) and other novel non-CRISPR editing platforms. Examples of key properties that seek to optimize include their efficiency (on-target activity), safety (reducing off-target activity), versatility and programmability (targeting range / ability to access the genome), precision (their edit outcomes), and other characteristics. Optimized proteins are developed via rational design, directed evolution, structure-guided engineering, machine learning, and additional approaches. We then translate these optimized tools into pre-clinical models and primary cell types to explore their potential to correct pathogenic mutations for a diverse set of diseases including liver-based disorders, inborn errors of immunity, neurological and neuromuscular, deafness, etc. The candidate will play an integral role in projects related to genome editing technology development, protein engineering method development, and expediting the clinical application of these tools.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Number of Employees
5,001-10,000 employees